FDA Invites Chat on Renewing Device Review Fees
Published Date: 6/11/2025
Notice
Summary
The FDA is gearing up to renew its Medical Device User Fee program from 2028 to 2032, which helps speed up the review of new medical devices. They’re hosting a public meeting and asking for your thoughts before the current program ends in September 2027. This means device makers and the public get a say in how fees are collected and used to keep medical innovation moving fast!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Device Fee Authority Expires 2027
If you make medical devices, the FDA's authority to collect device user fees ends on September 30, 2027. Congress must reauthorize the Medical Device User Fee Amendments for fiscal years 2028 through 2032 for the FDA to keep collecting those fees that fund device-application review.
Fees Fund Faster Device Reviews
You may get faster access to new medical devices if the Medical Device User Fee Amendments are reauthorized for fiscal years 2028 through 2032. The program lets FDA use collected fees to support the review of device applications; the current authority ends September 30, 2027.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-10550 — PSEG Nuclear LLC; Hope Creek Generating Station; License Amendment Request
PSEG Nuclear LLC wants to update its license for the Hope Creek Generating Station to allow a longer 24-month fuel cycle, meaning the plant can run longer between refueling. This change affects the plant’s operating rules and could improve efficiency without extra costs right now. The U.S. Nuclear Regulatory Commission is reviewing this request to keep things safe and smooth.
Next: 2025-10552 — Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Nurse Corps Scholarship Program
HRSA wants your thoughts on a new info collection for the Nurse Corps Scholarship Program, which helps nursing students pay for school. They’re checking if the paperwork is fair and not too much work before asking the big bosses at OMB for approval. If you’re a nurse, student, or just curious, now’s the time to speak up—this could affect how easy it is to get scholarships and when info is collected.